Preliminary study links long-term vaping with increased COPD risk

Person in black jacket exhaling large clouds of white vapor against an industrial concrete wall backdrop

A preliminary study of 22 young adults found that long-term vaping may lead to persistent lung function decline and increased COPD risk, though experts say larger studies with control groups are needed to confirm these findings.

  • Researchers measured forced expiratory volume (FEV1) in 22 e-cigarette users aged 21-35 over 12 months and found a decline of about 100mL per year
  • The study was published in Tobacco Control but had significant limitations including a small sample size, no nonsmoking control group, and only two measurement points
  • Experts like Dr. Lion Shahab noted the reported decline is more than twice the annual rate seen in current smokers, raising questions about study validity
  • Scientists agree this is an important research area but emphasize that larger, longer-term studies with proper control groups are needed before drawing firm conclusions

Long-term vaping in younger people may lead to persistent changes in lung function and an increased risk for COPD.

That’s according to the paper, “Prolonged Effect of E-cigarette Use on Pulmonary Function: A Pilot Study,” published in Tobacco Control.

The researchers said in a press release that, while the study does have shortcomings and further research is needed, preliminary results show the cumulative effects of vaping might lead to a decline in forced expiratory volume in the first second (FEV1).

The researchers analyzed the results of lung function tests from 22 current e-cigarette users aged 21-35 years. The tests were given once at the start of the study and again about 12 months later, and both were administered 12 hours after using any tobacco product.

The tests also measured forced vital capacity, which assesses the total volume of air that can be forcefully and rapidly exhaled from the lungs after taking a deep breath. The researchers looked at the ratio between the two measurements.

While the researchers admitted the study’s small size, constraint of two time points used for assessment and lack of a nontobacco control group were limiting factors, they said the results were enough to prompt future research.

“[The study] provides credible evidence of the effect of prolonged exposure to e-cigarette use on the pulmonary functions of young adults and its dose-response relation,” they wrote. “While an accelerated decline in FEV1 requires more lengthy observations and tobacco-free controls, the study provides the first indicator of the potential of prolonged e-cigarette use to have persistent and clinically important cumulative effects on FEV1 and pose a COPD risk.”

Others in the scientific community said that, while the study focuses on a worthwhile area of research, its shortcomings prevent it from being truly meaningful.

Katie East, MD, PhD, associate professor in public health at Brighton and Sussex Medical School in Brighton, Sussex, England, said in a press statement that far more research is needed before any conclusions can be reached.

“This is a small-scale pilot study of 22 people who had vaped in the past 30 days, with no control group,” she said. “Possible confounding with use of other tobacco products cannot be ruled out, since participants were eligible if they smoked five or less combustible tobacco products in the past month.”

Dr. East said that, while FEV1 declined as vaping frequency increased, the trend was not statistically significant, and the study doesn’t provide enough evidence to conclude that FEV1 volume differs by vaping frequency.

“This is an important research area. However, as the authors acknowledge, findings are preliminary,” she said. “Replication is required with larger studies, appropriate control groups and longer follow-up before reliable and meaningful conclusions can be drawn.”

Lion Shahab, PhD, professor of health psychology and co-director of the University College London Tobacco and Alcohol Research Group, was more critical of the study, citing several key areas where problems exist:

  • Lack of a nonsmoking comparison group
  • Participants were not required to be life-long smokers, meaning past or recent smoking could have contributed to any changes in lung function.
  • The size of the group in the study was too small
  • The study found no clear change in the FEV1/FVC ratio, which is the standard breathing test measure used to check for airflow obstruction in COPD

Dr. Shahab said there were also issues with the size of the reported changes in the study, which reported a drop of about 100mL over a year in FEV1. He said another larger comparison study, “Lung Function Decline in Former Smokers and Low-Intensity Current Smokers: A Secondary Data Analysis of the NHLBI Pooled Cohorts Study,” estimated annual declines at age 57 of about 31mL in people who had never smoked and 40 mL in current smokers.

“If the whole drop [in the new study] were due to vaping, it would be more than twice the annual decline reported for current smokers in [the larger] study,” he said. “An effect of that size is hard to square with the lack of a clear, large rise in respiratory disease among people who vape and have never smoked.”

Dr. Shahab said that taken together the limitations make it hard to draw firm conclusions about the impact of vaping on lung health, but he added it is still an important area to investigate.

“We need larger, more representative studies that compare people who vape and have never smoked with matched participants who neither smoke nor vape, and track changes in lung function over a longer period,” he said. 

More in COPD
Page 1 of 27
Next Page